Evidence map›Paper›PMID 21520273›Full record

ArticleGenetic epidemiology2011

Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.

Marinela Capanu, Patrick Concannon, Robert W Haile, Leslie Bernstein, Kathleen E Malone, Charles F Lynch, Xiaolin Liang, Sharon N Teraoka, Anh T Diep, Duncan C Thomas and 3 more

Abstract read
In one paragraph

Article in Genetic epidemiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marinela CapanuDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Patrick Concannon
Robert W Haile
Leslie Bernstein
Kathleen E Malone
Charles F Lynch
Xiaolin Liang
Sharon N Teraoka
Anh T Diep
Duncan C Thomas
Jonine L Bernstein
WECARE Study Collaborative Group
Colin B Begg

Funding

Genome-Wide Association Study of Radiation Exposure and Bilateral Breast CancerR01CA129639 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERNSTEIN, JONINE L. · 2009 to 2013
$15.6M
BREAST CANCER, RADIATION EXPOSURE, AND THE ATM GENEU01CA083178 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BERNSTEIN, JONINE LISA · 1999 to 2003
$9.3M
Interaction of Radiation, BRCA1/2, and Breast CancerR01CA097397 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BERNSTEIN, JONINE LISA · 2002 to 2006
$4.1M
Methods for Pathway Modeling with Application to FolateR01ES019876 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMAS, DUNCAN C. · 2010 to 2014
$2.9M
Statistical Methods in Genetic EpidemiologyR01AG014358 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HSU, LI · 2002 to 2013
$2.4M
Estimating Cancer Risks of Rare Genetic VariantsR01CA131010 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BEGG, COLIN B, CAPANU, MARINELA · 2008 to 2010
$944k
NCI NIH HHS CA083178NCI NIH HHS CA097397NCI NIH HHS CA131010NCI NIH HHS R01 CA097397NCI NIH HHS R01 CA129639NCI NIH HHS R01 CA131010NCI NIH HHS U01 CA083178NIA NIH HHS R01 AG014358NIEHS NIH HHS R01 ES019876
6 · The paper itself

Abstract

Current evidence suggests that the genetic risk of breast cancer may be caused primarily by rare variants. However, while classification of protein-truncating mutations as deleterious is relatively straightforward, distinguishing as deleterious or neutral the large number of rare missense variants is a difficult on-going task. In this article, we present one approach to this problem, hierarchical statistical modeling of data observed in a case-control study of contralateral breast cancer (CBC) in which all the participants were genotyped for variants in BRCA1 and BRCA2. Hierarchical modeling permits leverage of information from observed correlations of characteristics of groups of variants with case-control status to infer with greater precision the risks of individual rare variants. A total of 181 distinct rare missense variants were identified among the 705 cases with CBC and the 1,398 controls with unilateral breast cancer. The model identified three bioinformatic hierarchical covariates, align-GV, align-GD, and SIFT scores, each of which was modestly associated with risk. Collectively, the 11 variants that were classified as adverse on the basis of all the three bioinformatic predictors demonstrated a stronger risk signal. This group included five of six missense variants that were classified as deleterious at the outset by conventional criteria. The remaining six variants can be considered as plausibly deleterious, and deserving of further investigation (BRCA1 R866C; BRCA2 G1529R, D2665G, W2626C, E2663V, and R3052W). Hierarchical modeling is a strategy that has promise for interpreting the evidence from future association studies that involve sequencing of known or suspected cancer genes.

Indexed as

Genes, BRCA1Genes, BRCA2Genetic VariationBayes TheoremBreast NeoplasmsCase-Control StudiesFemaleGene FrequencyHumansLikelihood FunctionsModels, GeneticModels, StatisticalMutation, MissenseNeoplasms, Second PrimaryPolymorphism, Single NucleotideRisk Factors

Identifiers

PMID21520273
PMCPMC3111904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.